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Erythropoietin Restores C-Fiber Function and
Prevents Pressure Ulcer Formation in Diabetic Mice
Claire Demiot1, Vincent Sarrazy1, James Javellaud1, Loriane Gourloi1, Laurent Botelle1, Nicole Oudart1
and Jean-Michel Achard1
Pressure-induced vasodilatation (PIV), a cutaneous physiological neurovascular (C-fiber/endothelium) mech-
anism, is altered in diabetes and could possibly contribute to pressure ulcer development. We wanted to
determine whether recombinant human erythropoietin (rhEPO), which has protective neurovascular effects,
could prevent PIV alteration and pressure ulcer formation. We developed a skin pressure ulcer model in mice
by applying two magnetic plates to the dorsal skin. This induced significant stage 2 ulcers (assessed visually
and histologically) in streptozotocin-treated mice with 8 weeks of diabetes compared with very few in
controls. Control and streptozotocin mice received either no treatment or systematic rhEPO (3,000UI kg1 intra-
peritoneally, twice a week) during the last 2 weeks of diabetes. After 8 weeks of diabetes, we assessed ulcer
development, PIV, endothelium-dependent vasodilation, C-fiber-mediated nociception threshold, and skin
innervation density. Pretreatment with rhEPO fully prevented ulcer development in streptozotocin mice and
also fully restored C-fiber nociception, skin innervation density, and significantly improved PIV, but had no
effect on endothelium-dependent vasodilation. Our finding that rhEPO treatment protects the skin against
pressure-induced ulcers in diabetic mice encourages evaluation of the therapeutic potential for non-
hematopoietic analogs of EPO in preventing neuropathic diabetic ulcers.
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INTRODUCTION
Rigorous control of glycemia and blood pressure, and
lowering of cholesterol, has failed to reduce the risk of
diabetic feet (Urbancic-Rovan, 2005; Rajamani et al., 2009).
Owing to the devastating consequences in diabetic patients
and the major burden on health-care systems, any therapeutic
option able to decrease the necessity of amputation is highly
desirable.
Pressure-induced vasodilation (PIV) has been described as
being a cutaneous physiological neurovascular interaction
(Fromy et al., 1998, 2000b), delaying the occurrence of
tissue ischemia, and thus protecting the skin against pressure.
The increase in cutaneous blood flow in response to local
non-nociceptive pressure involves pressure sensing by
unmyelinated C-fibers, which function on the endothelium
to synthesize and release endothelial factors, such as nitric
oxide (Fromy et al., 2000b), inducing smooth muscle
relaxation. PIV is altered in diabetic humans (Koitka et al.,
2004) and diabetic mice with established neurovascular
dysfunctions (Demiot et al., 2006), which could favor
diabetic ulcer occurrence.
There are non-hematopoietic cellular targets of erythro-
poietin (EPO) in the skin, and the existence of EPO receptors
on endothelial cells (Anagnostou et al., 1994) and neurons
(Chen et al., 2010) has been described. There is also
experimental evidence that demonstrates that EPO has an
important function in skin wound healing (Galeano et al.,
2004, 2006; Hamed et al., 2010). Human recombinant EPO
(rhEPO) and non-hematopoietic analogs have been shown
to prevent and reverse diabetic neuropathy in rats and mice
(Bianchi et al., 2004; Leist et al., 2004). In addition, EPO
increases endothelial nitric oxide synthase expression and
stimulates nitric oxide release in cultured human endothelial
cells (Beleslin-Cokic et al., 2004). The dual neurovascular
nature of the defect responsible for PIV alteration in long-term
diabetes (Demiot et al., 2006) points to EPO as a potential
therapeutic tool for protecting skin from PIV alteration and
preventing pressure ulcer formation.
The objectives of this study were to determine whether
rhEPO could restore PIV in long-term diabetic mice with
established neurovascular dysfunction and prevent pressure-
induced skin ulcer formation.
RESULTS
At the time of experimentation (after 8 weeks of diabetes), all
diabetic mice lost significant weight and had significant
hyperglycemia compared with the respective control mice
(Table 1). Treatment with rhEPO during the last 2 weeks had
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no effect on weight and glycemia. The hematocrit of diabetic
animals was decreased compared with controls. RhEPO
increased the hematocrit in treated diabetic mice, but had no
effect in control mice. Neither the treatments nor diabetes
induction changed the systolic arterial blood pressure.
Effect of EPO on mechanical pressure algesia and skin
innervation
Untreated diabetic mice had mechanical hypoalgesia de-
tected using the tail pressure Randall–Sellito test (Figure 1a).
The tail pressure nociceptive threshold was significantly
increased by 57% in diabetic mice compared with control
mice (21.9±3 vs. 12.5±1g, Po0.01). The mechanical algesia
response observed in the rhEPO-treated diabetic group was
restored to the same level as its respective control group. In
control mice treated or untreated with rhEPO, protein gene
product 9.5 (PGP 9.5)-positive axons were evident in both the
dermis and epidermis of flank skin. In contrast, analysis of
PGP 9.5-positive axons in diabetic skin revealed an obvious
decrease in the general innervation of the skin. Visual
examination showed that rhEPO prevented this decrease
(Figure 1b). Quantification of PGP 9.5-positive axons in the
skin using axon tracing confirmed the visual observation
(Figure 1c). The skin areas occupied by labeled axons were
significantly reduced in diabetic mice compared with the
untreated control group. RhEPO treatment restored these areas
to the same level of labeled axons as the respective controls.
Effect of EPO on skin microcirculation reactivity
Cutaneous temperature and systolic arterial blood pressure
were stable throughout the experiment. Resting blood flow
was not significantly different between each group. In the
untreated control group, we observed an increase in laser
Doppler flowmetry (LDF) in response to iontophoretic deli-
very of acetylcholine, corresponding to a maximal percent-
age endothelium-dependent vasodilation of 28.5±3% from
baseline (Figure 2a). Diabetes caused a significant decrease
in acetylcholine-induced vasodilation that was not signi-
ficantly improved with EPO. Moreover, in all groups, LDF
increased in response to iontophoretic delivery of sodium
nitroprusside, and we did not observe any difference in the
endothelium-independent vasodilation between groups (control
41.5±7%, diabetic 65±8%, EPO-treated control 40±7.5%,
EPO-treated diabetic 52.5±10.5%; n¼8 in each group).
Table 1. Effects of EPO on body weight, glycemia,
hematocrit, and SABP in 8-week diabetic and control
mice on the day of the experiment
Group
Body
weight (g)
Glycemia
(mmol l1)
Hematocrit
(%)
SABP
(mmHg)
Control mice 43±1 7.2±0.4 51±1.5 64±3.5
Diabetic mice 28±1*** 25.9±2.1*** 39.5±2.5*** 73±6
Control mice+EPO 40±1 6.1±0.4 54±1 65±4.5
Diabetic mice+EPO 27±1*** 25.8±2.1*** 53±2w 65±5
Abbreviations: EPO, erythropoietin; rhEPO, recombinant human erythro-
poietin; SABP, systolic arterial blood pressure.
Control and 8-week diabetic mice were untreated or treated during the
last 2 weeks with rhEPO.
***Po0.001 versus respective control mice.
wPo0.05 versus diabetic mice.
n=10 in each group.
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Figure 1. Effect of erythropoietin (EPO) on skin neuropathy.
(a) Randall–Sellito tail pressure test. Mechanical withdrawal thresholds in
control and diabetic mice treated or not treated with recombinant human
erythropoietin (rhEPO). **Po0.01 versus respective control mice; wPo0.05
versus diabetic mice; n¼10 in each group. (b) Immunohistochemical
labeling of protein gene product 9.5 (PGP 9.5)-positive cutaneous axons
(white arrows) from the flank region. The dermis of control skin contains
horizontal PGP 9.5-positive nerve bundles. In contrast, diabetes causes an
obvious decrease in dermal and epidermal innervations. RhEPO restores
general innervation. Original magnification 200; bar (white)¼100 mm;
‘‘F’’ denotes hair follicles. (c) Abundance of PGP 9.5-positive axons in the skin
from the flank. The percentage of skin area occupied by immunopositive
axons is shown. **Po0.01 versus respective control mice; wPo0.05 versus
diabetic mice; n¼ 12 in each group.
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Effect of EPO on PIV
Cutaneous temperature and systolic arterial blood pressure
were stable throughout the experiment. In the untreated
control group, LDF increased in response to increasing local
pressure that reached a maximal value at 0.4 kPa correspond-
ing to a PIV of þ34.7±8.5% from baseline. In contrast, in
the untreated diabetic group, LDF decreased in response
to local pressure applied at 0.4 kPa (Figure 2b). RhEPO
treatment had a significantly beneficial effect on PIV in
diabetic mice compared with untreated diabetic mice, but
failed to restore a normal PIV in diabetic mice compared with
the treated control group.
Effect of EPO on macroscopic and histological findings in the
pressure ulcer model
3H pressure. In untreated control mice, the mean percentage
of stage 2 ulcer areas at days 2 and 3 (Figure 3e) and
histological scores were low (Figure 3f). In contrast, daily
progression of a superficial pressure ulcer (stage X2) with
partial-thickness skin loss involving the epidermis and dermis
was observed in the center of the compressed area in diabetic
mice (Figure 3a). Stage 2 ulcer surface reached a maximum
at days 2 and 3 (Figure 3e). Histopathology showed
epidermal and superficial dermis defects with necrotic areas
in the dermis (Figure 3b), giving a histological score of
2.75±0.3 at day 1 and 2.9±0.35 at day 3 (Figure 3f). Treat-
ment with rhEPO in control mice had no effect. The mean
percentage of stage 2 ulcer areas at days 2 and 3 (Figure 3e)
and histological scores (Figure 3f) were not different from
that of untreated control mice. In diabetic mice, however,
treatment with rhEPO markedly and significantly reduced
ulcer development (Figure 3c). Histological examination
showed the presence of three skin layers, and sometimes
a thickening of the epithelium and disruption of fibers
(Figure 3d), with a score of 0.91±0.2 at day 1 and
0.83±0.1 at day 3 (Figure 3f).
12H pressure in non-diabetic mice. Stage 2 ulcer area
development in control mice after 12 hours of pressure was
similar to that observed in diabetic mice after 3 hours of
pressure stage 2 ulcer surfaces (% in compressed area): at
day 1, day 2, and day 3, they were 19.0±3.7%, 29.1±3.0%,
and 26.5±3.3%, respectively, and were not different
from the respective values observed in the group of mice
pretreated with rhEPO during 2 weeks (11.9±2.9%,
23.7±3.4%, and 33.8±3.2%; n¼ 10 in each group).
DISCUSSION
The main findings of our study are that rhEPO treatment
administered for 2 weeks in mice with diabetes of 6 weeks
duration with established neuropathy (1) fully restored the
loss of unmyelinated C-fibers in the skin and restored
functional hypoalgesia (2) significantly but incompletely
improved PIV, and (3) had no effect on diabetes-induced
endothelial dysfunction in skin microcirculation.
In addition, our study demonstrated that rhEPO was able
to fully prevent ulcer development induced by one single
high pressure in advanced diabetes with neuropathy.
Our study thus confirms the well-documented potent
neuroprotective and neurorepairing effects of EPO. Similar to
diabetic patients, mice with streptozotocin-induced diabetes
develop peripheral diabetic neuropathy with alterations in
nociceptive thermal and mechanical thresholds (Uehara
et al., 2004; Vinik and Mehrabyan, 2004). The first fibers
affected in diabetic neuropathy are the small sensory ones
(Vinik and Mehrabyan, 2004). In Swiss mice, thermal hypo-
algesia develops after only 2 weeks of streptozotocin-induced
diabetes, and a measurable reduction in PGP 9.5-immuno-
reactive epidermal nerve fiber density is present after 4 weeks
(Beiswenger et al., 2008). In our model, as anticipated, treat-
ment with rhEPO for 2 weeks administered after 6 weeks
of diabetes was sufficient to fully restore a normal skin
innervation density that functionally correlated with the
recovery of a normal nociceptive threshold in diabetic mice.
In contrast to its neuroprotective effect, rhEPO had no
effect on the deleterious effect of long-lasting diabetes on
endothelial dysfunction. As a result, rhEPO treatment signi-
ficantly improved, but failed to fully restore PIV in diabetic
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Figure 2. Effect of erythropoietin (EPO) on skin microcirculation reactivity
alteration. (a) Endothelium-dependent vasodilation. Maximal percentage
of vasodilation from baseline in response to iontophoretic delivery of
acetylcholine (ACh) in control and diabetic mice treated or not treated with
recombinant human erythropoietin (rhEPO), n¼ 8 in each group. (b) Pressure-
induced vasodilation. Maximal percentage of vasodilation from baseline
during local pressure application in control and diabetic mice treated or
not treated with rhEPO, n¼10 in each group. *Po0.05, **Po0.01,
***Po0.001 versus respective control mice; wwPo0.01 versus diabetic
mice. LDF, laser Doppler flowmetry.
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mice. These mixed results contrast with the fact that rhEPO,
nonetheless, fully prevented skin ulceration in response to
pressure. It is possible that the improvement in PIV, although
incomplete, was nonetheless sufficient to provide diabetic
skin with the ability to resist pressure. Conversely, these
results may suggest that the ability of rhEPO to prevent ulcer
formation is independent of PIV in our specific experimental
conditions. Indeed, the idea that failure of a physiological
adaptation to pressure, increasing skin blood flow, could be
central to the pathogenesis of diabetic ulcers is intuitively
compelling. However, it is worth noting that the pressure
threshold that elicited the maximal increase in flow (0.4 kPa,
i.e. 3mmHg) was almost three orders of magnitude lower
than the pressure applied to skin with magnets (estimated
about 2,000mmHg). Under such conditions, blood flow
necessarily stopped within the compressed skin areas,
whether PIV was present or not. This suggests that the pro-
tective effect of rhEPO was the consequence of its ability to
restore effective mechanisms in diabetic mice, enabling the
deleterious effects of ischemia and/or reperfusion in skin
cells to be overcome. However, this protective effect of
rhEPO most certainly did not result from a hemodynamic
mechanism, which preserved some degree of tissue perfusion
during exposure to pressure.
It is nonetheless possible that rhEPO may have exerted
its protective effects by increasing the hematocrit, through
increasing tissue oxygenation during reperfusion, once
pressure had been released. The ability of systemic admin-
istration of EPO to accelerate wound closure in various
models of skin excision (Galeano et al., 2004), such as burns
(Galeano et al., 2006) and ischemic wounds (Buemi et al.,
2004), has been reported repeatedly. This effect appears to be
independent of hematocrit changes as the non-erythropoietic,
tissue-protective derivatives, carbamylated EPO and ARA
290, are highly effective in facilitating wound healing
(Erbayraktar et al., 2009), and as topical administration of
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Figure 3. Effect of erythropoietin (EPO) on cutaneous macroscopic and histological findings following 3 hours of pressure. Representative photographs
of skin compressed areas and central histological skin compressed sections in untreated (a, b) and in recombinant human erythropoietin (rhEPO)-treated
diabetic (c, d) at days 1–3. Histological section: hematoxylin and eosin staining; original magnification  100; bar¼ 100mm. (e) Time course of macroscopic
stage 2 ulcer areas: control, n¼ 13; diabetic mice, n¼ 12; rhEPO-treated control, n¼ 13; rhEPO-treated diabetic mice, n¼10. ***Po0.001 versus respective
control mice; wwwPo0.001 versus diabetic mice. (f ) Central histological pressure ulcer score in control and diabetic mice treated or not treated with rhEPO.
***Po0.001 versus respective control mice; wwwPo0.001 versus diabetic mice; n¼ 6 in each group.
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rhEPO, while devoid of a systemic erythropoietic effect,
improves wound repair in the skin of diabetic rats and mice
(Hamed et al., 2010, 2011). However, wound repair and
formation of ulcers in response to pressure are clearly distinct
processes, so that the beneficial mechanisms of EPO in both
settings are not necessarily the same. The observed regression
of diabetic neuropathy together with protection against
ulcer formation with EPO is in good agreement with the
well-established clinical risk of skin ulceration in pressure-
exposed areas in patients with sensitive neuropathy
(including diabetic neuropathy; Urbancic-Rovan, 2005).
Interestingly, the common understanding is that sensory
neuropathy renders the foot ‘‘deaf and blind’’ to stimuli,
normally provoking pain or discomfort, therefore exposing
the foot to repetitive trauma, which may then go unnoticed
until ulceration occurs. However, in our experimental
conditions, the mice had no way at escaping the pressure
stimuli. This suggests that, in addition to impairing nocicep-
tion, the alteration of skin nerve fibers may impede the
normal protective response of the skin to ischemia.
However, our results do not enable us to formally
conclude that there is a causal relationship between the
neuroprotective effect and pressure ulcer prevention induced
by rhEPO. We decided to test the hypothesis that pressure
ulcer prevention in the skin could reflect the general property
of rhEPO to improve tissue tolerance to ischemia–reperfusion,
which has been demonstrated in numerous other organs
such as the heart (Shen et al., 2010), kidney (Ishii et al., 2010),
testis (Ergur et al., 2008), and intestine (Sayan et al., 2009),
independently of its neurotrophic action. We therefore
conducted an additional set of experiments in normal non-
diabetic mice. We increased the time of skin exposure to
pressure to 12hours in order to induce skin ulcers in non-
diabetic mice comparable to that induced in diabetic mice
after only 3hours. Pretreatment with rhEPO had no effect
on the severity of ulcer development in non-diabetic skin.
Taken together, our findings suggest that rhEPO has a specific
protective effect on pressure-induced ulcers in diabetic skin
only. Although consistent with the hypothesis that the
protection against pressure ulcer is the consequence of the
functional neuroprotection, a firm conclusion is, however,
prevented by the fact that, under our experimental conditions,
treatment with rhEPO normalized hematocrit in anemic
diabetic mice, but unexpectedly failed to significantly increase
it in control mice. Our findings thus stress the need for further
studies to determine whether non-erythropoietic analogs of
EPO share similar protective effects in diabetic mice.
Prevention is fundamental in avoiding diabetic foot ulcers
and amputation. To date, this strategy is primarily based on
identifying high-risk patients, providing education about
appropriate foot care, and implementing measures to prevent
ulceration such as protective footwear and podiatry. The
FIELD (fenofibrate intervention and event lowering in
diabetes) study has recently provided a breakthrough in
amputation prevention (Rajamani et al., 2009). This random-
ized controlled trial performed in Type 2 diabetic patients
showed that patients receiving fenofibrate had a significantly
reduced amputation risk compared with patients receiving
placebo. The reduction was particularly substantial (hazard
ratio 0.53) for minor amputation risk in patients without
large-vessel disease, and was most likely explained by non-
lipid mechanisms. Beyond establishing the potential benefit
of fenofibrate per se, this cornerstone study demonstrates for
the first time that reducing the risk of amputation in diabetic
patients using a pharmacological approach is a reachable
goal. This should encourage the search for other drugs
that may also be effective, in order to go even further in
amputation prevention. Our preclinical study identifies
rhEPO as such a candidate drug. Much caution is, however,
required before implementing a clinical study to examine
whether this experimental protective effect of rhEPO trans-
lates into efficient protection in diabetic patients. Chronic use
of rhEPO in non-anemic patients would expose them to
an undesirable increase in hematocrit. Furthermore, the
TREAT (Trial to Reduce Cardiovascular Events With Aranesp
Therapy) trial recently demonstrated that even in diabetic
patients with mild anemia, the deleterious side effects of
rhEPO may overcome its benefits (Solomon et al., 2010). This
has prompted the discovery of the new derivatives that retain
the tissue-protective effects of rhEPO, but are devoid of
hematopoietic properties and their related side effects such
as venous thromboembolisms (Hand and Brines, 2010).
Our results thus strongly encourage evaluation of the thera-
peutical potential of these new compounds in the prevention
of neuropathic diabetic ulceration.
MATERIALS AND METHODS
Male Swiss mice aged 5–6 weeks (20–30 g) were randomly assigned
to four weight-matched experimental groups—untreated controls,
rhEPO-treated controls, untreated diabetic mice, and rhEPO-treated
diabetic mice–and maintained on a 12-h light/dark cycle with
food and water available ad libitum. Diabetes was induced by a
single intraperitoneal injection of streptozotocin (200mg kg1;
Sigma-Aldrich, Lyon, France). Hyperglycemia occurred 2 days
after streptozotocin injection and was verified using an Accu-Check
Active glucometer (Roche, Lyon, France). Mice included in the
diabetic groups were excluded when blood glucose was
o16mmol l1 2 days after injection. Treatment with rhEPO (Roche;
3,000UI kg1 intraperitoneally, twice a week, or saline) was
implemented after 6 weeks of diabetes duration for two additional
weeks. Assessment of skin neurovascular alterations and exposure to
pressure were performed after 8 weeks of diabetes.
The current investigation conformed to the guidelines for ethical
care of experimental animals of the European Community and was
approved by the French Agriculture Ministry (authorization no.
B-00889).
Mechanical pressure algesia
Tail pressure thresholds were registered with the Paw/Tail Pressure
Analgesia meter for the Randal–Sellito test (Bioseb, Vitrolles, France).
Pressure increasing at a linear rate of 16 g s1, with a cutoff at 250 g
to avoid tissue injury, was applied to the base of the tail. The applied
tail pressure that evoked biting or licking behavior was registered
and expressed in grams. Three tests separated by at least 15minutes
were performed for each animal, and the mean value of these tests
was calculated.
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Skin innervation density
Flank skin was dissected, fixed overnight in buffered 4% formal-
dehyde solution, embedded in Finetek Tissue-Tek Compound
(Sakura, Chikuma, Japan), and then frozen at 20 1C. Sections were
cut on a cryostat at 20 mm and incubated overnight with primary
antibodies to PGP 9.5 (1:3,000; Chemicon, Temecula, CA), which
labels all sensory and autonomic axons in skin biopsies from a
variety of species, including both normal and diabetic rats and mice
(Dalsgaard et al., 1989; Wilkinson et al., 1989). After washing,
sections were incubated with secondary antibody Alexa Fluor 594
(goat anti-rabbit from Dako, Cergy Pontoise, France; 1:4,000),
followed by 5minutes of incubation with 40,6-diamidino-2-phenyl-
indole (Sigma-Aldrich) to stain the cell nucleus. Quantification of
skin innervation density was performed using previously published
protocols by Christianson et al. (2003). Briefly, sequential slides from
each animal were stained and then coded to ensure that the observer
was unaware of the identity of the animal. Fluorescent-labeled
sections were viewed using a Leica microscope and analyzed by the
Leica IM-500 software (Nanterre, France). Percentage of skin area
(mm2) occupied by axons was measured with an image analyzer
(Perfect-Image, Clara Vision, Orsay, France). Four sections were
traced for each animal from all four groups.
Skin microcirculation reactivity
Hair of the animals was removed 2 days before experiments, with
depilatory lotion to obtain a hairless area for skin LDF measure-
ments, local pressure application, and iontophoretic delivery. For
experiments, animals were anesthetized with thiopental sodium
(65mg kg1 intraperitoneally) and then placed in an incubator
(Mediprema, Tours, France) warmed to maintain a stable cutaneous
temperature (35.0±0.5 1C). Non-invasive blood pressure (Bionic
Instruments, Tokyo, Japan) was recorded before and after experi-
ments to verify systolic arterial blood pressure stability.
Endothelium-independent and -dependent responses. Skin
blood flow was recorded, using a laser Doppler multifiber probe
(481-1; Perimed, Stockholm, Sweden), during transcutaneous
iontophoresis applied to a 1.2-cm2 area on the hairless back of
animals. This method was described by Demiot et al. (2006), using
cathodal sodium nitroprusside iontophoretic delivery (endothelium-
independent assessment) and anodal acetylcholine iontophoretic
delivery (endothelium-dependent assessment). We recorded skin
blood flow baselines before endothelium-dependent and -indepen-
dent response assessment. Vasodilator responses were reported as
the maximal percentage increase from baseline in response to
iontophoretic delivery of sodium nitroprusside and acetylcholine,
respectively.
Pressure-induced vasodilation. Skin blood flow in response to
local pressure was measured by LDF. This method was described by
Fromy et al. (2000a), using a weighbridge that was adapted to hold a
laser Doppler probe at one end (PF 408, Periflux; Perimed). The
probe was connected to a laser Doppler flowmeter (PF5000 Master,
Periflux; Perimed). The weighbridge was carefully equilibrated, with
the probe placed in the middle of the hairless skull and external
pressure was increased progressively at 2.2 Pa s1 through the laser
Doppler probe, using a syringe pump. The LDF signal was digitized
with a 20-Hz sampling frequency, using a computerized acquisition
system (Biopac, Santa Barbara, CA). Data collection started with
a 1-min control period before the onset of increasing pressure.
Pressure ulcer model
Pressure ulcers were created on the dorsum of mice as described by
Stadler et al. (2004). The dorsal hair was shaved. After 24 hours, the
skin was gently pulled up and placed between two round ceramic
magnetic plates (10mm diameter and 1mm thick, with an average
weight of 0.5 g and 10,000 Gauss magnetic force). Epidermis, dermis,
and subcutaneous tissue layer, but not muscles, were pinched with
the magnetic plates. This process created a compressive pressure of
approximately 2,000mmHg between the two magnets. A pressure
greater than 400mmHg has been estimated to be necessary to
maintain microvascular closure in mouse dorsal skin (Tsuji et al.,
2005). In preliminary experiments, an exposure to pressure during
12hours was shown to reproducibly elicit a skin ulcer in normal mice;
a shorter exposure (3hours) did not induce skin ulceration in normal
mice, but was sufficient to induce an ulcer in diabetic mice.
Macroscopic and microscopic analysis of pressure ulcer
For the analysis of pressure ulcer, each compressed area was
photographed using a 3.3megapixel camera (Photo PC 3100Z;
Epson, Nagano, Japan). Pressure ulcers were staged by visual
assessment according to the standardized ulcer scale (Tsuji et al.,
2005). We delimited the compressed area and skin ulcer area
percentage was calculated in the total compressed area using an
image analyzer (Clara Vision, Orsay, France). After the mice were
killed, six compressed tissue samples at days 1 and 3 were dissected
from the flank, fixed overnight in buffered 4% formaldehyde
solution, embedded in Finetek Tissue-Tek Compound, and then
frozen at 20 1C. Sections of 12 mm were stained with hematoxylin
and eosin. The samples were analyzed with an optical microscope
(Leica). Histological examination was based on histological mod-
ification of the three skin layers and lack of tissue depth in the center
of the sections (score 0: no histological modification of three skin
layers; score 1: three skin layers with disruption of fibers and
histological epidermis modification; score 2: epidermal defect with
necrotic areas in dermis; score 3: superficial dermal defect with
necrotic regions; and score 4: deep dermal defect).
Statistical analysis
Data were expressed as mean±SE. They were first subjected to
Bartlett’s test for homogeneity of variances. One-way analysis of
variance was followed by the Student–Newman–Keuls multiple
range tests to estimate the significance of differences for between-
group comparisons. Within a group (untreated, treated with rhEPO),
control and diabetic mice were compared using an unpaired t-test.
To study ulcer development, we used a paired t-test. Significance
was defined at Po0.05.
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